Libtayo (cemiplimab-rwlc) / Regeneron 
Welcome,         Profile    Billing    Logout  
 1 Disease   67 Trials   67 Trials   1555 News 


«12...2728293031323334353637...3940»
  • ||||||||||  Hiltonol (poly-ICLC) / Oncovir
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 (clinicaltrials.gov) -  Feb 1, 2021   
    P1/2,  N=7, Terminated, 
    The administrative responsibilities have been met with extraordinary challenges. Current funding does not match the incurring costs.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Trial completion date, Trial primary completion date:  Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies (clinicaltrials.gov) -  Jan 27, 2021   
    P1/2,  N=134, Active, not recruiting, 
    Trial completion date: Mar 2023 --> Jan 2024 | Trial primary completion date: May 2022 --> Mar 2023 Trial completion date: Jun 2021 --> Mar 2021 | Trial primary completion date: Jun 2021 --> Mar 2021
  • ||||||||||  BNT112 / BioNTech
    Enrollment change, Monotherapy:  PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (clinicaltrials.gov) -  Jan 14, 2021   
    P1/2,  N=130, Recruiting, 
    N=100 --> 0 | Not yet recruiting --> Withdrawn N=80 --> 130
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
    New P1/2 trial, PD(L)-1 Biomarker, IO biomarker:  LAG3 PET Imaging in Advanced Solid Tumors (clinicaltrials.gov) -  Jan 12, 2021   
    P1/2,  N=38, Not yet recruiting, 
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, Checkpoint inhibition:  Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. (Pubmed Central) -  Jan 3, 2021   
    Besides, the newly detected predictors of response will (hopefully) be of great helps in selecting the subset of patients that might benefit the most from this class of drugs. Finally, new trials are in the starting blocks, and they are expected to shed in the next future new light on a therapy, which is considered a milestone in oncology.
  • ||||||||||  Libtayo (cemiplimab) / Sanofi, Regeneron
    Review, Journal:  Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma. (Pubmed Central) -  Dec 31, 2020   
    Overall, cemiplimab has a durable, clinically significant effect and an acceptable tolerability and safety profile. As the first approved treatment for this indication, cemiplimab represents a welcome therapeutic advance for patients with advanced CSCC.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] Evaluating the recurrence of immune-mediated toxicities in cancer patients after rechallenge with a checkpoint inhibitor () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_4553;    
    Data from patients that have been rechallenged on an ICI after experiencing an immune-mediated adverse event will be reviewed and used to evaluate the incidence of immune-mediated toxicity recurrence and whether or not the toxicity occurred in the same organ system as the initial toxicity. This information will also be used to describe corticosteroid dosing and duration following immune-mediated toxicities and evaluate the drug and patient characteristics that may predispose patients to developing immune-mediated toxicities.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] Identifying rare toxicities of immune checkpoint inhibitors in adults with cancer () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_4024;    
    The primary endpoint is to identify rare toxicities of immune checkpoint inhibitors that may be underreported in the literature. Secondary endpoints include the incidence of immune-mediated adverse events and appropriate side effect management per National Comprehensive Cancer Network (NCCN) guidelines.
  • ||||||||||  Odomzo (sonidegib) / Sun Pharma, Libtayo (cemiplimab-rwlc) / Regeneron
    New P2 trial:  Anti-PD1-antibody and Pulsed HHI for Advanced BCC (clinicaltrials.gov) -  Dec 22, 2020   
    P2,  N=20, Not yet recruiting, 
  • ||||||||||  Hiltonol (poly-ICLC) / Oncovir
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol (clinicaltrials.gov) -  Dec 17, 2020   
    P2,  N=26, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | N=100 --> 26 | Trial completion date: Dec 2021 --> Aug 2020 | Trial primary completion date: Jun 2021 --> Aug 2020
  • ||||||||||  Hiltonol (poly-ICLC) / Oncovir
    Enrollment closed:  Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 (clinicaltrials.gov) -  Dec 17, 2020   
    P1/2,  N=60, Active, not recruiting, 
    Thus, baseline PD-L1 expression levels may be used to identify patients with advanced NSCLC who are most likely to derive greatest benefit from 1L cemiplimab monotherapy. Recruiting --> Active, not recruiting
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Trial completion date, Trial primary completion date:  A Study of Isatuximab-based Therapy in Participants With Lymphoma (clinicaltrials.gov) -  Nov 17, 2020   
    P1/2,  N=130, Active, not recruiting, 
    Phase classification: P1b/2 --> P1/2 Trial completion date: Nov 2023 --> Dec 2022 | Trial primary completion date: Nov 2023 --> Dec 2022